Are all the IL-23 blockers the same in inflammatory bowel disease?,Nature Reviews Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Nat. Rev. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Are all the IL-23 blockers the same in inflammatory bowel disease?
Nature Reviews Gastroenterology & Hepatology ( IF 45.9 ) Pub Date : 2024-01-05 , DOI: 10.1038/s41575-023-00889-7
Silvio Danese _{1,

2} , Laurent Peyrin-Biroulet _{3,

4}

Affiliation

A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.

中文翻译：